Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07454187) titled 'To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Condition:
Relapsed/Refractory Multiple Myeloma
Intervention:
Drug: SG2918
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 14, 2026
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07454187
Pu...